{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T02:48:42Z","timestamp":1794019722951,"version":"4.8.0"},"reference-count":123,"publisher":"American Medical Association (AMA)","issue":"14","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2026,10,13]]},"abstract":"<jats:sec id=\"ab-jrv260019-1\">\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Rheumatoid arthritis (RA) is a chronic autoimmune disease that causes inflammation and destruction of cartilage and adjacent bone and can lead to irreversible disability. Rheumatoid arthritis affects 0.53% of adults worldwide and 0.74% of US adults.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-jrv260019-2\">\n                    <jats:title>Observations<\/jats:title>\n                    <jats:p>Rheumatoid arthritis is more common among females than males (2:1) and has a peak incidence at ages 55 to 75 years. Rheumatoid arthritis can affect all synovial joints, and extra-articular involvement may include rheumatoid nodules, vasculitis, and rheumatoid lung disease. At diagnosis, approximately 40% to 60% of patients have autoantibodies (eg, rheumatoid factor and\/or anticitrullinated peptide antibodies). There are no formal diagnostic criteria for RA, so the diagnosis is based on clinical history, characteristic joint swelling in proximal interphalangeal, metacarpophalangeal, and\/or wrist joints and often presence of autoantibodies and elevated C-reactive protein levels. Early diagnosis, ideally within 6 weeks of symptom onset, allows rapid initiation of therapy with disease-modifying antirheumatic drugs (DMARDs), which inhibit inflammation and decrease the risk of joint destruction. The goal of treatment is to achieve at least 50% improvement in disease activity by 3 months and remission or low disease activity at 6 months, measured by validated indexes such as the Clinical Disease Activity Index (CDAI). The European Alliance of Associations for Rheumatology recommends starting treatment with methotrexate, 7.5 mg to 10 mg orally weekly, increasing to 20 mg to 25 mg weekly within 4 to 8 weeks, and considering addition of short-term glucocorticoids (eg, prednisone, 5-7.5 mg\/d), tapered and discontinued within 3 months, or 1 intramuscular injection of 80 mg to 160 mg depot methylprednisolone. For patients with contraindications to methotrexate, sulfasalazine (2-4 g\/d) or leflunomide (20 mg\/d) is recommended. With treatment, about 40% of patients with newly diagnosed RA achieve CDAI remission within 6 months. Patients who do not achieve remission with first-line DMARDs should be prescribed biological DMARDs (eg, tumor necrosis factor \u03b1 inhibitors, costimulation inhibitors, interleukin 6 receptor inhibitors, anti-CD20\u2013targeting B cells), or Janus kinase (JAK) inhibitors (in patients not at high risk of thromboembolism, cardiovascular disease, or malignancy). With addition of biological DMARDs or JAK inhibitors to first-line DMARDs, overall remission or low disease activity rates increase to approximately 80%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-jrv260019-3\">\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>Rheumatoid arthritis is a chronic autoimmune disease that causes joint destruction. First-line initial therapy is methotrexate, with consideration of glucocorticoids as additive therapy. For patients who do not achieve remission with this initial treatment, adding biological DMARDs or JAK inhibitors increases overall remission or low disease activity rates to 80%.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jama.2026.15455","type":"journal-article","created":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T15:00:19Z","timestamp":1789052419000},"page":"1257","source":"Crossref","is-referenced-by-count":2,"title":["Rheumatoid Arthritis in Adults"],"prefix":"10.1001","volume":"336","author":[{"given":"Josef S.","family":"Smolen","sequence":"first","affiliation":[{"name":"Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Kerschbaumer","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria"},{"name":"Division of Immunology and Rheumatology, Stanford University, Stanford, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Aletaha","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William H.","family":"Robinson","sequence":"additional","affiliation":[{"name":"Division of Immunology and Rheumatology, Stanford University, Stanford, California"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"4","key":"jrv260019r1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI178722","article-title":"Estimation of prevalence of autoimmune diseases in the United States using electronic health record data.","volume":"135","author":"Abend","year":"2024","journal-title":"J Clin Invest"},{"issue":"1","key":"jrv260019r2","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/s41927-025-00570-3","article-title":"Rheumatoid arthritis continues to increase in low-middle SDI and low SDI quintiles based on GBD 1990-2021.","volume":"9","author":"Fu","year":"2025","journal-title":"BMC Rheumatol"},{"issue":"9","key":"jrv260019r3","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1007\/s00393-025-01628-w","article-title":"A comparative assessment of rheumatoid arthritis burden: trends in China, the US, India, Europe, and globally from 1990 to 2021 and forecasts to 2030 utilizing GBD data.","volume":"84","author":"Yang","year":"2025","journal-title":"Z Rheumatol"},{"issue":"6","key":"jrv260019r4","doi-asserted-by":"publisher","first-page":"983","DOI":"10.3899\/jrheum.101133","article-title":"Incidence of extraarticular rheumatoid arthritis in Olmsted County, Minnesota, in 1995-2007 versus 1985-1994: a population-based study.","volume":"38","author":"Myasoedova","year":"2011","journal-title":"J Rheumatol"},{"issue":"1","key":"jrv260019r5","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1136\/annrheumdis-2013-204223","article-title":"Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA).","volume":"73","author":"Dougados","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"jrv260019r6","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1016\/j.ard.2026.01.023","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biologic disease-modifying antirheumatic drugs: 2025 update.","volume":"85","author":"Smolen","year":"2026","journal-title":"Ann Rheum Dis"},{"issue":"13","key":"jrv260019r7","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1001\/jama.2018.13103","article-title":"Diagnosis and management of rheumatoid arthritis: a review.","volume":"320","author":"Aletaha","year":"2018","journal-title":"JAMA"},{"issue":"10","key":"jrv260019r8","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1172\/JCI0215582","article-title":"Osteoclasts are essential for TNF-a\u2013mediated joint destruction.","volume":"110","author":"Redlich","year":"2002","journal-title":"J Clin Invest"},{"issue":"5","key":"jrv260019r9","first-page":"1607","article-title":"Synovial fibroblasts of patients with rheumatoid arthritis attach to and invade normal human cartilage when engrafted into SCID mice.","volume":"149","author":"M\u00fcller-Ladner","year":"1996","journal-title":"Am J Pathol"},{"issue":"9","key":"jrv260019r10","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1038\/s41584-018-0070-0","article-title":"Rheumatoid arthritis and the mucosal origins hypothesis: protection turns to destruction.","volume":"14","author":"Holers","year":"2018","journal-title":"Nat Rev Rheumatol"},{"issue":"4","key":"jrv260019r11","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1136\/annrheumdis-2018-213678","article-title":"Genetics of rheumatoid arthritis: 2018 status.","volume":"78","author":"Okada","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"jrv260019r12","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1038\/s41588-023-01586-6","article-title":"Mapping the dynamic genetic regulatory architecture of HLA genes at single-cell resolution.","volume":"55","author":"Kang","year":"2023","journal-title":"Nat Genet"},{"issue":"570","key":"jrv260019r13","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaz5327","article-title":"Persistently activated, proliferative memory autoreactive B cells promote inflammation in rheumatoid arthritis.","volume":"12","author":"Kristyanto","year":"2020","journal-title":"Sci Transl Med"},{"issue":"9","key":"jrv260019r14","doi-asserted-by":"publisher","first-page":"3098","DOI":"10.4049\/jimmunol.140.9.3098","article-title":"Antigenic specificities of human monoclonal and polyclonal IgM rheumatoid factors: the C gamma 2\u2013C gamma 3 interface region contains the major determinants.","volume":"140","author":"Sasso","year":"1988","journal-title":"J Immunol"},{"key":"jrv260019r15","doi-asserted-by":"publisher","first-page":"ii132","DOI":"10.1136\/annrheumdis-2012-202349","article-title":"Autoimmunity in rheumatoid arthritis: different antigens\u2014common principles.","volume":"72","author":"Trouw","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"jrv260019r16","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2022.100519","article-title":"Rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis epidemiology in England from 2004 to 2020: an observational study using primary care electronic health record data.","volume":"23","author":"Scott","year":"2022","journal-title":"Lancet Reg Health Eur"},{"issue":"6","key":"jrv260019r17","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1002\/art.27425","article-title":"Is the incidence of rheumatoid arthritis rising? results from Olmsted County, Minnesota, 1955-2007.","volume":"62","author":"Myasoedova","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"10","key":"jrv260019r18","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1093\/rheumatology\/32.10.903","article-title":"Twin concordance rates for rheumatoid arthritis: results from a nationwide study.","volume":"32","author":"Silman","year":"1993","journal-title":"Br J Rheumatol"},{"issue":"6","key":"jrv260019r19","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/S1297-319X(03)00141-6","article-title":"Smoking, gender and rheumatoid arthritis\u2014epidemiological clues to etiology: results from the Behavioral Risk Factor Surveillance System.","volume":"70","author":"Krishnan","year":"2003","journal-title":"Joint Bone Spine"},{"issue":"9","key":"jrv260019r20","doi-asserted-by":"publisher","first-page":"2662","DOI":"10.1002\/art.27552","article-title":"Peptidylarginine deiminase from Porphyromonas gingivalis citrullinates human fibrinogen and a-enolase: implications for autoimmunity in rheumatoid arthritis.","volume":"62","author":"Wegner","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"1","key":"jrv260019r21","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1136\/ard.2008.102962","article-title":"Gene-environment interaction between HLA-DRB1 shared epitope and heavy cigarette smoking in predicting incident rheumatoid arthritis.","volume":"69","author":"Karlson","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"jrv260019r22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0139693","article-title":"Rheumatoid arthritis risk associated with periodontitis exposure: a nationwide, population-based cohort study.","volume":"10","author":"Chou","year":"2015","journal-title":"PLoS One"},{"issue":"4","key":"jrv260019r23","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1093\/rheumatology\/kead345","article-title":"Presence of periodontal disease and the incidence of inflammatory arthritides in the general population: data from the UK Biobank.","volume":"63","author":"Yun","year":"2024","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"jrv260019r24","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1038\/s41588-018-0102-3","article-title":"Transcription factors operate across disease loci, with EBNA2 implicated in autoimmunity.","volume":"50","author":"Harley","year":"2018","journal-title":"Nat Genet"},{"issue":"4","key":"jrv260019r25","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1002\/art.41994","article-title":"Antibody responses to Epstein-Barr virus in the preclinical period of rheumatoid arthritis suggest the presence of increased viral reactivation cycles.","volume":"74","author":"Fechtner","year":"2022","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"jrv260019r26","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.shaw.2020.02.001","article-title":"The association between occupational exposure to silica and risk of developing rheumatoid arthritis: a meta-analysis.","volume":"11","author":"Mehri","year":"2020","journal-title":"Saf Health Work"},{"issue":"1","key":"jrv260019r27","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2021-002055","article-title":"Association between long-term exposure to air pollution and immune-mediated diseases: a population-based cohort study.","volume":"8","author":"Adami","year":"2022","journal-title":"RMD Open"},{"issue":"1","key":"jrv260019r28","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.rdc.2005.09.005","article-title":"The definition and measurement of disease modification in inflammatory rheumatic diseases.","volume":"32","author":"Aletaha","year":"2006","journal-title":"Rheum Dis Clin North Am"},{"issue":"1","key":"jrv260019r29","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1002\/art.1780380106","article-title":"Validity and reliability of the twenty-eight-joint count for the assessment of rheumatoid arthritis activity.","volume":"38","author":"Smolen","year":"1995","journal-title":"Arthritis Rheum"},{"issue":"6","key":"jrv260019r31","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1136\/ard.57.6.350","article-title":"Magnetic resonance imaging of the wrist in early rheumatoid arthritis reveals a high prevalence of erosions at four months after symptom onset.","volume":"57","author":"McQueen","year":"1998","journal-title":"Ann Rheum Dis"},{"key":"jrv260019r32","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.ejim.2024.04.026","article-title":"Incidence and predisposing factors of extra-articular manifestations in contemporary rheumatoid arthritis.","volume":"126","author":"Ljung","year":"2024","journal-title":"Eur J Intern Med"},{"issue":"10","key":"jrv260019r33","first-page":"2074","article-title":"Rheumatoid factor and antibodies to cyclic citrullinated peptide differentiate rheumatoid arthritis from undifferentiated polyarthritis in patients with early arthritis.","volume":"29","author":"Jansen","year":"2002","journal-title":"J Rheumatol"},{"issue":"1","key":"jrv260019r34","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1002\/art.10727","article-title":"Influence of disease-modifying therapy on radiographic outcome in inflammatory polyarthritis at five years: results from a large observational inception study.","volume":"48","author":"Bukhari","year":"2003","journal-title":"Arthritis Rheum"},{"issue":"10","key":"jrv260019r35","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1093\/rheumatology\/kev131","article-title":"Estimating the diagnostic accuracy of rheumatoid factor in UK primary care: a study using the Clinical Practice Research Datalink.","volume":"54","author":"Miller","year":"2015","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"jrv260019r36","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/s13075-019-1909-8","article-title":"Outcome of patients with early arthritis without rheumatoid factor and ACPA and predictors of rheumatoid arthritis in the ESPOIR cohort.","volume":"21","author":"Mouterde","year":"2019","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"jrv260019r37","first-page":"380","article-title":"Anemia in early rheumatoid arthritis is associated with interleukin 6-mediated bone marrow suppression, but has no effect on disease course or mortality.","volume":"35","author":"Nikolaisen","year":"2008","journal-title":"J Rheumatol"},{"issue":"7","key":"jrv260019r38","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1002\/acr.22583","article-title":"Distinctions between diagnostic and classification criteria?","volume":"67","author":"Aggarwal","year":"2015","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"9","key":"jrv260019r39","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1136\/ard.2010.138461","article-title":"2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative.","volume":"69","author":"Aletaha","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"jrv260019r40","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1136\/annrheumdis-2012-202779","article-title":"EULAR definition of erosive disease in light of the 2010 ACR\/EULAR rheumatoid arthritis classification criteria.","volume":"72","author":"van der Heijde","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"jrv260019r41","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1002\/art.20018","article-title":"Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors.","volume":"50","author":"Nielen","year":"2004","journal-title":"Arthritis Rheum"},{"issue":"9","key":"jrv260019r42","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1016\/j.ard.2025.01.021","article-title":"EULAR\/ACR risk stratification criteria for development of rheumatoid arthritis in the risk stage of arthralgia.","volume":"84","author":"van Steenbergen","year":"2025","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"jrv260019r43","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.1136\/ard.2010.131201","article-title":"Clinical synovitis in a particular joint is associated with progression of erosions and joint space narrowing in that same joint, but not in patients initially treated with infliximab.","volume":"69","author":"Klarenbeek","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"jrv260019r44","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1136\/ard.2010.138693","article-title":"Physical disability in rheumatoid arthritis is associated with cartilage damage rather than bone destruction.","volume":"70","author":"Aletaha","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"jrv260019r45","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1136\/annrheumdis-2015-208941","article-title":"Targeting ultrasound remission in early rheumatoid arthritis: the results of the TaSER study, a randomised clinical trial.","volume":"75","author":"Dale","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"jrv260019r46","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1002\/art.1780360601","article-title":"The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials.","volume":"36","author":"Felson","year":"1993","journal-title":"Arthritis Rheum"},{"issue":"5","key":"jrv260019r47","first-page":"S14","article-title":"The Health Assessment Questionnaire (HAQ).","volume":"23","author":"Bruce","year":"2005","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"jrv260019r48","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1136\/ard-2022-223413","article-title":"American College of Rheumatology\/EULAR remission criteria for rheumatoid arthritis: 2022 revision.","volume":"82","author":"Studenic","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"jrv260019r49","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1002\/acr.24596","article-title":"2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis.","volume":"73","author":"Fraenkel","year":"2021","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"1","key":"jrv260019r50","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1002\/art.21519","article-title":"The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment.","volume":"54","author":"Breedveld","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"1","key":"jrv260019r51","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1136\/annrheumdis-2015-209057","article-title":"Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naive patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III study.","volume":"76","author":"Emery","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"jrv260019r52","doi-asserted-by":"publisher","first-page":"m4328","DOI":"10.1136\/bmj.m4328","article-title":"Active conventional treatment and three different biological treatments in early rheumatoid arthritis: phase IV investigator initiated, randomised, observer blinded clinical trial.","volume":"371","author":"Hetland","year":"2020","journal-title":"BMJ"},{"issue":"9149","key":"jrv260019r53","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/S0140-6736(98)09403-3","article-title":"Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial.","volume":"353","author":"Smolen","year":"1999","journal-title":"Lancet"},{"key":"jrv260019r54","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1093\/rheumatology\/XXXIV.suppl_2.35","article-title":"Clinical efficacy of sulphasalazine\u2014a review.","volume":"34","author":"Capell","year":"1995","journal-title":"Br J Rheumatol"},{"issue":"2","key":"jrv260019r55","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1136\/ard.2006.057133","article-title":"Combination therapy with sulfasalazine and methotrexate is more effective than either drug alone in patients with rheumatoid arthritis with a suboptimal response to sulfasalazine: results from the double-blind placebo-controlled MASCOT study.","volume":"66","author":"Capell","year":"2007","journal-title":"Ann Rheum Dis"},{"issue":"8688","key":"jrv260019r56","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/0140-6736(90)90771-V","article-title":"Sulphasalazine versus hydroxychloroquine in rheumatoid arthritis: 3-year follow-up.","volume":"335","author":"van der Heijde","year":"1990","journal-title":"Lancet"},{"issue":"6","key":"jrv260019r57","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1056\/NEJMoa1112072","article-title":"Tofacitinib or adalimumab versus placebo in rheumatoid arthritis.","volume":"367","author":"van Vollenhoven","year":"2012","journal-title":"N Engl J Med"},{"issue":"9865","key":"jrv260019r58","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/S0140-6736(12)61424-X","article-title":"Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial.","volume":"381","author":"Burmester","year":"2013","journal-title":"Lancet"},{"issue":"10093","key":"jrv260019r59","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/S0140-6736(17)31618-5","article-title":"Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b\/4, double-blind, head-to-head, randomised controlled trial.","volume":"390","author":"Fleischmann","year":"2017","journal-title":"Lancet"},{"issue":"5","key":"jrv260019r60","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/j.ard.2025.01.032","article-title":"Expert consensus statement on the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: 2024 update.","volume":"84","author":"Nash","year":"2025","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"jrv260019r61","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1136\/annrheumdis-2016-210094","article-title":"Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study.","volume":"76","author":"Dougados","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"13","key":"jrv260019r62","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1056\/NEJMoa1507247","article-title":"Baricitinib in patients with refractory rheumatoid arthritis.","volume":"374","author":"Genovese","year":"2016","journal-title":"N Engl J Med"},{"issue":"7","key":"jrv260019r63","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1056\/NEJMoa1608345","article-title":"Baricitinib versus placebo or adalimumab in rheumatoid arthritis.","volume":"376","author":"Taylor","year":"2017","journal-title":"N Engl J Med"},{"issue":"7","key":"jrv260019r64","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1136\/annrheumdis-2020-219214","article-title":"Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial.","volume":"80","author":"Combe","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"jrv260019r65","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1001\/jama.2019.9055","article-title":"Effect of filgotinib vs placebo on clinical response in patients with moderate to severe rheumatoid arthritis refractory to disease-modifying antirheumatic drug therapy: the FINCH 2 randomized clinical trial.","volume":"322","author":"Genovese","year":"2019","journal-title":"JAMA"},{"issue":"10139","key":"jrv260019r66","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1016\/S0140-6736(18)31115-2","article-title":"Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial.","volume":"391","author":"Burmester","year":"2018","journal-title":"Lancet"},{"issue":"10139","key":"jrv260019r67","doi-asserted-by":"publisher","first-page":"2513","DOI":"10.1016\/S0140-6736(18)31116-4","article-title":"Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial.","volume":"391","author":"Genovese","year":"2018","journal-title":"Lancet"},{"issue":"11","key":"jrv260019r68","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1136\/annrheumdis-2019-215764","article-title":"Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response.","volume":"78","author":"Fleischmann","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"jrv260019r69","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1136\/annrheumdis-2019-215164","article-title":"Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III randomised, double-blind, placebo-controlled trial (RAJ4) in Japan.","volume":"78","author":"Takeuchi","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"jrv260019r70","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1136\/ard-2023-224477","article-title":"Determination of the most appropriate ACR response definition for contemporary drug approval trials in rheumatoid arthritis.","volume":"83","author":"Konzett","year":"2024","journal-title":"Ann Rheum Dis"},{"issue":"9685","key":"jrv260019r71","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/S0140-6736(09)60506-7","article-title":"Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor a inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial.","volume":"374","author":"Smolen","year":"2009","journal-title":"Lancet"},{"issue":"12","key":"jrv260019r72","doi-asserted-by":"publisher","first-page":"2204","DOI":"10.1093\/rheumatology\/kes150","article-title":"Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: results from the REALISTIC phase IIIb study.","volume":"51","author":"Weinblatt","year":"2012","journal-title":"Rheumatology"},{"issue":"9617","key":"jrv260019r73","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1016\/S0140-6736(08)60453-5","article-title":"Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial.","volume":"371","author":"Smolen","year":"2008","journal-title":"Lancet"},{"issue":"11","key":"jrv260019r74","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1136\/ard.2008.092932","article-title":"IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial.","volume":"67","author":"Emery","year":"2008","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"jrv260019r75","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1002\/art.39093","article-title":"Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a phase III study.","volume":"67","author":"Genovese","year":"2015","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"jrv260019r76","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1002\/art.39944","article-title":"Sarilumab and nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis and inadequate response or intolerance to tumor necrosis factor inhibitors.","volume":"69","author":"Fleischmann","year":"2017","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"jrv260019r77","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1002\/art.21778","article-title":"The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial.","volume":"54","author":"Emery","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"9","key":"jrv260019r78","doi-asserted-by":"publisher","first-page":"2793","DOI":"10.1002\/art.22025","article-title":"Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks.","volume":"54","author":"Cohen","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"10041","key":"jrv260019r79","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/S0140-6736(16)00380-9","article-title":"Tumour necrosis factor inhibition versus rituximab for patients with rheumatoid arthritis who require biological treatment (ORBIT): an open-label, randomised controlled, non-inferiority, trial.","volume":"388","author":"Porter","year":"2016","journal-title":"Lancet"},{"issue":"12","key":"jrv260019r80","doi-asserted-by":"publisher","first-page":"865","DOI":"10.7326\/0003-4819-144-12-200606200-00003","article-title":"Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial.","volume":"144","author":"Kremer","year":"2006","journal-title":"Ann Intern Med"},{"issue":"11","key":"jrv260019r81","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1056\/NEJMoa050524","article-title":"Abatacept for rheumatoid arthritis refractory to tumor necrosis factor a inhibition.","volume":"353","author":"Genovese","year":"2005","journal-title":"N Engl J Med"},{"issue":"1","key":"jrv260019r82","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/annrheumdis-2015-207524","article-title":"Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force.","volume":"75","author":"Smolen","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"jrv260019r83","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1002\/art.20982","article-title":"Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of the ATTRACT study.","volume":"52","author":"Smolen","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"5","key":"jrv260019r84","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1136\/annrheumdis-2021-221323","article-title":"Baricitinib further enhances disease-modifying effects by uncoupling the link between disease activity and joint structural progression in patients with rheumatoid arthritis.","volume":"81","author":"Lopez-Romero","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"9430","key":"jrv260019r85","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/S0140-6736(04)16676-2","article-title":"Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial.","volume":"364","author":"Grigor","year":"2004","journal-title":"Lancet"},{"issue":"11","key":"jrv260019r86","doi-asserted-by":"publisher","first-page":"3381","DOI":"10.1002\/art.21405","article-title":"Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial.","volume":"52","author":"Goekoop-Ruiterman","year":"2005","journal-title":"Arthritis Rheum"},{"key":"jrv260019r87","doi-asserted-by":"crossref","first-page":"119","DOI":"10.2147\/PPA.S192008","article-title":"Effect of patient education on medication adherence of patients with rheumatoid arthritis: a randomized controlled trial.","volume":"13","author":"Taibanguay","year":"2019","journal-title":"Patient Prefer Adherence"},{"issue":"7","key":"jrv260019r88","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1136\/ard.2008.092668","article-title":"Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature.","volume":"68","author":"Visser","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"jrv260019r89","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1002\/1529-0131(200107)44:7<1515::AID-ART273>3.0.CO;2-7","article-title":"Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty-eight week, multicenter, randomized, double-blind, placebo-controlled study.","volume":"44","author":"van Ede","year":"2001","journal-title":"Arthritis Rheum"},{"issue":"9","key":"jrv260019r90","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1007\/s10067-022-06221-z","article-title":"Oral methotrexate at doses 15-25 mg\/week is non-inferior to parenteral regarding efficacy and safety in the treatment of rheumatoid arthritis: a systematic review and meta-analysis.","volume":"41","author":"Wang","year":"2022","journal-title":"Clin Rheumatol"},{"issue":"6","key":"jrv260019r91","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1136\/annrheumdis-2016-210715","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update.","volume":"76","author":"Smolen","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"jrv260019r92","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.ard.2025.03.002","article-title":"Treatment with methotrexate plus oral prednisolone versus triple therapy (methotrexate\/sulfasalazine\/hydroxychloroquine) plus intra-articular glucocorticoids in early rheumatoid arthritis: a prespecified nonrandomised subgroup analysis of clinical and radiographic data at 48 weeks from the NORD-STAR trial\u2019s conventional treatment arm.","volume":"84","author":"Hetland","year":"2025","journal-title":"Ann Rheum Dis"},{"issue":"21","key":"jrv260019r93","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1001\/archinte.159.21.2542","article-title":"Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate.","volume":"159","author":"Strand","year":"1999","journal-title":"Arch Intern Med"},{"issue":"3","key":"jrv260019r94","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.reuma.2017.07.020","article-title":"Systematic review and meta-analysis of the efficacy and safety of leflunomide and methotrexate in the treatment of rheumatoid arthritis.","volume":"15","author":"Alfaro-Lara","year":"2019","journal-title":"Reumatol Clin (Engl Ed)"},{"issue":"6","key":"jrv260019r95","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1136\/annrheumdis-2016-210713","article-title":"Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis.","volume":"76","author":"Nam","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"jrv260019r96","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1136\/annrheumdis-2013-204577","article-title":"Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis.","volume":"73","author":"Nam","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"jrv260019r97","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1136\/annrheumdis-2014-206106","article-title":"Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period.","volume":"74","author":"Emery","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"jrv260019r98","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1136\/annrheumdis-2015-208426","article-title":"Comparison of adding tocilizumab to methotrexate with switching to tocilizumab in patients with rheumatoid arthritis with inadequate response to methotrexate: 52-week results from a prospective, randomised, controlled study (SURPRISE study).","volume":"75","author":"Kaneko","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"jrv260019r99","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1136\/annrheumdis-2013-204769","article-title":"Efficacy and safety of ascending methotrexate dose in combination with adalimumab: the randomised CONCERTO trial.","volume":"74","author":"Burmester","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"jrv260019r100","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1136\/ard.2006.066761","article-title":"Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial.","volume":"66","author":"Burmester","year":"2007","journal-title":"Ann Rheum Dis"},{"issue":"9877","key":"jrv260019r101","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(13)60250-0","article-title":"Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial.","volume":"381","author":"Gabay","year":"2013","journal-title":"Lancet"},{"issue":"5","key":"jrv260019r102","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1136\/annrheumdis-2016-210310","article-title":"Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial.","volume":"76","author":"Burmester","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"jrv260019r103","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1136\/ard-2023-223850","article-title":"Selectivity, efficacy and safety of JAKinibs: new evidence for a still evolving story.","volume":"83","author":"Bonelli","year":"2024","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"jrv260019r104","doi-asserted-by":"crossref","first-page":"178","DOI":"10.3390\/ph18020178","article-title":"Comparative efficacy and safety of JAK inhibitors in the management of rheumatoid arthritis: a network meta-analysis.","volume":"18","author":"Almoallim","year":"2025","journal-title":"Pharmaceuticals (Basel)"},{"key":"jrv260019r105","article-title":"Comparative efficacy and safety of JAK inhibitors as monotherapy and in combination with methotrexate in patients with active rheumatoid arthritis: a systematic review and meta-analysis.","volume":"13","author":"Liu","year":"2022","journal-title":"Front Immunol"},{"issue":"4","key":"jrv260019r106","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis.","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N Engl J Med"},{"issue":"8","key":"jrv260019r109","first-page":"3834","article-title":"Risk of serious infections in arthritis patients treated with biological drugs: a matched cohort study and development of prediction model.","volume":"60","author":"Krabbe","year":"2021","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"jrv260019r110","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jbspin.2016.02.028","article-title":"Safety of biologic DMARDs in RA patients in real life: a systematic literature review and meta-analyses of biologic registers.","volume":"84","author":"de La Forest Divonne","year":"2017","journal-title":"Joint Bone Spine"},{"issue":"6","key":"jrv260019r111","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/j.ard.2026.02.024","article-title":"Safety of synthetic and biological DMARDs: a systematic literature review informing the 2025 update of the EULAR recommendations for the management of rheumatoid arthritis.","volume":"85","author":"Laskou","year":"2026","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"jrv260019r112","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.ard.2025.01.024","article-title":"Safety of Janus kinase inhibitors in immune-mediated inflammatory diseases\u2014a systematic literature review informing the 2024 update of an international expert consensus statement.","volume":"84","author":"Konzett","year":"2025","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"jrv260019r113","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbspin.2026.106080","article-title":"Real-world comparison of herpes zoster risk among five Janus kinase inhibitors in rheumatoid arthritis: the ANSWER cohort study.","volume":"93","author":"Etani","year":"2026","journal-title":"Joint Bone Spine"},{"key":"jrv260019r114","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2022.152120","article-title":"Opportunistic infections associated with Janus kinase inhibitor treatment for rheumatoid arthritis: a structured literature review.","volume":"58","author":"Winthrop","year":"2023","journal-title":"Semin Arthritis Rheum"},{"issue":"3","key":"jrv260019r115","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1002\/acr.25045","article-title":"2022 American College of Rheumatology guideline for vaccinations in patients with rheumatic and musculoskeletal diseases.","volume":"75","author":"Bass","year":"2023","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"1","key":"jrv260019r116","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1136\/ard-2022-223357","article-title":"Safety of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis.","volume":"82","author":"Sepriano","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"jrv260019r117","first-page":"s310a","article-title":"Long-term safety evaluation of baricitinib vs TNF inhibitors in rheumatoid arthritis patients selected for venous thrombo-embolism risk.","volume":"85","author":"Taylor","year":"2026","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"jrv260019r118","doi-asserted-by":"crossref","first-page":"5073","DOI":"10.1093\/rheumatology\/keab398","article-title":"Current favourable 10-year outcome of patients with early rheumatoid arthritis: data from the ESPOIR cohort.","volume":"60","author":"Combe","year":"2021","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"jrv260019r119","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1093\/rheumatology\/kew004","article-title":"Have radiographic progression rates in early rheumatoid arthritis changed? a systematic review and meta-analysis of long-term cohorts.","volume":"55","author":"Carpenter","year":"2016","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"jrv260019r120","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1136\/annrheumdis-2013-204021","article-title":"Mortality in rheumatoid arthritis: the impact of disease activity, treatment with glucocorticoids, TNFa inhibitors and rituximab.","volume":"74","author":"Listing","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"jrv260019r121","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1002\/acr.25026","article-title":"Influence of smoking on disease activity and quality of life in patients with rheumatoid arthritis: results from a Swedish case-control study with longitudinal follow-up.","volume":"75","author":"Alfredsson","year":"2023","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"10","key":"jrv260019r122","doi-asserted-by":"crossref","first-page":"3226","DOI":"10.1002\/art.22943","article-title":"Disease activity early in the course of treatment predicts response to therapy after one year in rheumatoid arthritis patients.","volume":"56","author":"Aletaha","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"2","key":"jrv260019r123","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1136\/annrheumdis-2017-211937","article-title":"Consensus-based recommendations for the use of biosimilars to treat rheumatological diseases.","volume":"77","author":"Kay","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"jrv260019r30","author":"Strand","year":"2014"},{"key":"jrv260019r107","unstructured":"US Food and Drug Administration. Initial safety trial results find increased risk of serious heart-related problems and cancer with arthritis and ulcerative colitis medicine Xeljanz, Xeljanz XR (tofacitinib). Published February 4, 2021. Accessed July 29, 2026. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/initial-safety-trial-results-find-increased-risk-serious-heart-related-problems-and-cancer-arthritis"},{"key":"jrv260019r108","unstructured":"European Medicines Agency. Xeljanz (tofacitinib): increased risk of major adverse cardiovascular events and malignancies with use of tofacitinib relative to TNF-alpha inhibitors. Published June 7, 2021. Accessed July 29, 2026. https:\/\/www.ema.europa.eu\/en\/medicines\/dhpc\/xeljanz-tofacitinib-increased-risk-major-adverse-cardiovascular-events-malignancies-use-tofacitinib"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2853931\/jama_smolen_2026_rv_260019_1790887511.09385.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T15:00:34Z","timestamp":1791903634000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2853931"}},"subtitle":["A Review"],"short-title":[],"issued":{"date-parts":[[2026,10,13]]},"references-count":123,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2026,10,13]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2026.15455","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10,13]]}}}